Fertility warning
This medicine may affect fertility.
Leaflet MYLERAN 2mg film-coated tablets
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Busulfan is a chemotherapeutic medication primarily used for the treatment of chronic myeloid leukemia (CML) and as part of conditioning regimens prior to hematopoietic stem cell transplantation. It is an alkylating agent that interferes with the DNA of cancer cells, inhibiting cell division and causing cell death.
The medication is administered orally or intravenously, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer, the patient's overall condition, and their response to treatment.
Common side effects include nausea, vomiting, diarrhea, fatigue, and decreased blood cell counts, which may increase the risk of infections. In rare cases, more severe adverse effects such as pulmonary toxicity, hepatotoxicity, or infertility may occur.
Busulfan is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, regular monitoring during treatment is essential to detect and manage potential adverse effects.
The medication is administered orally or intravenously, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer, the patient's overall condition, and their response to treatment.
Common side effects include nausea, vomiting, diarrhea, fatigue, and decreased blood cell counts, which may increase the risk of infections. In rare cases, more severe adverse effects such as pulmonary toxicity, hepatotoxicity, or infertility may occur.
Busulfan is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, regular monitoring during treatment is essential to detect and manage potential adverse effects.
General data about MYLERAN 2mg
- Substance:
- busulfan
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W58856002
- Concentration:
- 2mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 100
- Product type:
- Original
- Price:
- 345.08 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for busulfan
Concentrations available for busulfan
- 2mg
- 6mg/ml